Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

计划入组 23 人 · 首次发布于 2008 年 12 月 2 日

Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors

计划入组 12 人 · 首次发布于 2017 年 9 月 12 日

AntiCEA M3-I

计划入组 20 人

M3 Muscarinic Antagonists (UCB)

Muscarinic M3 antagonists (Nuada)

long-acting muscarinic M3 antagonists (AstraZeneca)

M3 Health

Australia

M3, INC.

Japan

Harmony Biosciences

United States

Zydus Healthcare Secures CDSCO Approval for Phase III Trials of Two COPD Combination Therapies

Zydus Healthcare to Conduct Phase III Trial for Glycopyrrolate/Indacaterol Inhaler

FDA Approves Cobenfy, a Novel Muscarinic Receptor-Targeting Drug for Schizophrenia